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Abstract
Hyperglycemia has become an important risk factor for mortality 
and morbidity in the neonatal period, especially with increased sur-
vival rates of very low birth weight neonates. Hyperglycemia in the 
neonatal period develops as a result of various mechanisms includ-
ing iatrogenic causes, inability to supress hepatic glucose produc-
tion, insulin resistance or glucose intolerance, specifically in preterm 
neonates. Initiation of parenteral or enteral feeding in the early pe-
riod in preterm babies increases insulin production and sensitivity. 
The plasma glucose is targeted to be kept between 70 and 150 mg/
dL in the newborn baby. While a blood glucose value above 150 mg/
dL is defined as hyperglycemia, blood glucose values measured with 
an interval of 4 hours of >180-200 mg/dL and +2 glucosuria require 
treatment. Although glucose infusion rate is reduced in treatment, 
use of insulin is recommended, if two blood glucose values mea-
sured with an interval of 4 hours are >250 mg/dL and glucosuria is 
present in two separate urine samples.
Keywords: Glucosuria, hyperglycemia, newborn, preterm, Very low 
birth weight baby
Öz
Yenidoğan döneminde özellikle çok düşük doğum ağırlıklı be-
beklerin yaşamda kalmaya başlamaları ile birlikte, hiperglisemi 
morbidite ve mortalite için önemli bir risk etmeni olmuştur. Ye-
nidoğan döneminde özellikle preterm bebeklerde hiperglisemi, 
iyatrojenik nedenler, karaciğerde glukoz üretiminin baskılanama-
ması, insülin direnci ya da glukoz intoleransı gibi mekanizmalar 
sonucu gelişmektedir. Preterm bebeklerin erken dönemde paren-
teral ya da enteral beslenmeye başlanması; insülin yapımını ve 
duyarlılığını arttırır. Yenidoğan bebekte kan şekerinin 70-150 mg/
dL arasında olması hedeflenmektedir. Kan şeker düzeyi >150 mg/
dL olması hiperglisemi olarak tanımlanırken; 4 saat ara ile bakılan 
kan şekerinin >180-200 mg/dL olması ve +2 glukozüri olması teda-
viyi gerektirmektedir. Tedavide glukoz infüzyon hızı azaltılmasına 
rağmen; 4 saat ara ile bakılan 2 kan şekeri değeri >250 mg/dL ve 
alınan iki ayrı idrar örneğinde glukozüri varsa insülin kullanılması 
önerilmektedir.
Anahtar sözcükler: Aşırı düşük doğum ağırlıklı bebek, glukozüri, hi-
perglisemi, preterm, yenidoğan
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Glucose balance in the neonatal period
In early postnatal period, newborn infants provide to 
maintain glucose homeostasis via glycogenolysis and 
gluconeogenesis. It is important for the cental nervous 
system just after birth. In very-low-birth-weight (VLBW) 
neonates and preterms, the balance is impaired when a 
limited reserve is combined with the increased energy re-
quirement of the newborn. In this period, the frequency 
of hypoglycemia is increased, but hyperglycemia is not 
rare. Hyperglycemia develops as a result of the inability 
of the newborn to decrease endogenous glucose produc-
tion during parenteral glucose infusion or the inability to 
increase peripheral glucose use (1, 2).
Definition and follow-up
Although there is no consensus about the safe range of 
glucose concentration, a blood glucose level of 70-150 mg/
dL is targeted. In newborn babies, a blood glucose level 
above 150 mg/dL is defined as hyperglycemia (3). In the 
follow-up of VLBW neonates, hyperglycemia is associated 
with intracranial hemorrhage, stage 2/3 necrotizing ente-
rocolitis (NEC), increased risk for sepsis, retinopathy of pre-
maturity (ROP), conditions where stress load is increased, 
surgical interventions, ventilator treatment, growth re-
tardation, and increased mortality. Severe hyperglycemia 
in the early period in VLBW neonates is an independent 
risk factor for increased mortality. Hyperglycemia should 
be prevented in all newborn babies. However, there is no 
established blood glucose level for the development of 
these outcomes. Although values including 150 -154 -180 
-220 mg/dL have been specified in various studies, it has 
been reported that serious outcomes would develop with 
long-term increased blood glucose levels (4). Persisting 
hyperglycemia, which develops suddenly in the absence a 
change in infusion rate frequently is the result of sepsis or 
endocrine problems in the neonatal period (4).
In preterm and VLBW babies, a blood glucose level of 
>180-200 mg/dL indicates the presence of a problem, but 
clinically important hyperglycemia is defined as osmotic 
diuresis and glucosuria. It has been reported that it is more 
important to monitor the blood glucose level in associa-
tion with monitoring of development of osmotic diuresis, 
rather than monitoring the blood glucose level alone. In 
clinical practice, the presence of glucosuria (>1% gluco-
suria) (1000 mg/dL) is defined as the marker of osmolarity 
change, which necessitates close glucose monitoring (2).
A blood glucose level measured as >180-200 mg/dL with a 
4-hour interval and glucosuria of +2 necessitates treatment.
Causes of hyperglycemia (1-16):
1. Iatrogenic hyperglycemia: Erroneous calculation of 
intravenous (IV) fluids may lead to hyperglycemia. Par-
enteral glucose treatment is administered in neonatal in-
tensive care units (NICUs) in preterm babies (long-term 
in small preterms) and ill term-newborns because of de-
layed enteral feeding. This may generally create a risk in 
terms of hyperglycemia in newborns and iatrogenic hy-
perglycemia may take time. The initiation of glucose in-
fusion at a dosage of 4-6 mg/kg/min on the first day with 
the objective of preventing hypoglycemia in preterms or 
in all ill newborns protects babies from hypoglycemia and 
potential hyperglycemia.
2. Inability to metabolize glucose: Hyperglycemia may be 
related to prematurity. In very young infants who often 
receive total parenteral nutrition, hyperglycemia may de-
velop secondary to glucose intolerance or secondary to 
sepsis and stress.
3. Impaired glucose homeostasis: VLBW neonates (<1000 
g) have increased fluid requirement because of underde-
veloped renal function and excessive insensible fluid loss. 
Therefore, giving excessive glucose in association with 
high volume fluid may lead to hyperglycemia in these 
neonates. In addition, these neonates have insulin resis-
tance and delayed insulin response. Even in the absence 
of a high glucose infusion rate, hyperglycemia may be ob-
served because of inadequate insulin secretion and inabil-
ity to suppress glucose production in the liver. In addition, 
impaired glucose homeostasis may lead to transient hy-
perglycemia in “small-for-gestational-age” (SGA) babies.
4. Giving hyperosmolar formula: Hyperosmolarity may de-
velop as a result of preparing formula with less water than 
needed. This may lead to transient neonatal glucose intol-
erance in the baby. Severe dehydration, hypernatremia, and 
hyperglycemia may develop in relation to gastroenteritis.
5. Convulsions: Hyperglycemia may develop due to cate-
cholamine secretion.
6. 46, XXDq deletion of chromosome 13: Hyperglycemia 
may be observed.
7. Lipid infusion: Hyperglycemia may develop even if the rate 
of glucose administration is low in infants receiving lipid in-
fusions. Increased plasma free fatty acid concentration may 
lead to  hyperglycemic response which  in turn inhibits the 
peripheral use of glucose and inhibit the effects of insulin. 
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8. Protein intake in the early period: Early protein intake 
influences the release of insulin-like growth factor-1 (IGF 
1). IGF 1 lowers blood glucose by increasing the use of 
peripheral glucose, increasing glycogen synthesis and 
suppressing hepatic glucose production. Relative insulin 
deficiency in the preterm infant causes a low level of IGF 
1, which  prevents the development of pancreas and beta 
cells and develops hyperglycemia.
9. Sepsis: If hyperglycemia develops in normoglycemic 
and clinically stable neonates without a change in glucose 
infusion rate, the possibility of sepsis and NEC should be 
considered.
10. Stress: Conditions including pain, hypoxia, and respira-
tory distress cause hyperglycemia secondary to increased 
cortisol and catecholamine levels in the neonates. The 
blood glucose level may increase after surgical procedures.
11. Drugs: Maternal use of diazoxide and neonatal use 
of caffeine, steroids, and phenytoin may lead to hyper-
glycemia.
12. Diabetes mellitus in newborns
Diagnostic approach
Physical examination: 
There are no significant, specific findings related to hy-
perglycemia. Physical examination may reveal signs of 
sepsis such as temperature instability and peripheral per-
fusion.
Laboratory:
1. Serum glucose level: Measurements with “dextrostix” 
have a high probability of yielding erroneous results. 
Serum glucose level must be measured before starting 
treatment.
Which method should be used to measure the blood glu-
cose level in the neonatal period? 
ASPEN recommends the use of venous blood glucose 
measurements rather than capillary blood glucose mea-
surement because capillary blood indicates the level in 
whole blood, which is 15% lower and is influenced by 
dilution with alcohol and by increased hematocrit value. 
However, it is appropriate to monitor blood glucose by 
capillary measurements because it will not be possible to 
obtain venous blood each time blood glucose measure-
ment is needed in NICUs (15). Continuous glucose mea-
surement (CGM) systems may be used because the num-
ber of interventions is high, the risk for hypoglycemia 
and hyperglycemia cannot be determined, and interim 
measurements cannot be found with capillary blood 
glucose measurements. CGM devices are also useful in 
demonstrating glucose trends other than showing glu-
cose values. (17, 18).
2. Detection of glucose in urine: Glucosuria is a finding of 
osmotic diuresis. A glucose value of 2+ or higher the in 
urine increases the risk on osmotic diuresis. Each 18 mg/
dL increase in blood glucose increases serum osmolarity 
by 1 mOsm/L. Normal osmolarity is 280-300 mOsm/L.
3. Complete blood count: Complete blood count is essen-
tial for differential diagnosis of sepsis.
4. Serum electrolytes: Hyperglycemia causes electrolyte 
loss in urine by leading to osmotic diuresis. Electrolyte 
levels should be monitored in patients with hyper-
glycemia. 
5. Serum insulin level: Serum insulin levels may be low or 
low-normal in transient diabetes mellitus in newborns.
6. Serum and urine C-peptide levels: These levels are used 
in the differential diagnosis of monogenic diabetes and 
Type 1 diabetes.
Treatment 
In the treatment of hyperglycemia; reducing the amount 
of glucose given or initiating insulin therapy or both 
should be performed together (19).
Most infants who are not fed are initially given 4-6 mg 
/ kg / min iv glucose to maintain normal blood glucose 
levels. Blood glucose is generally measured every 4-6 
hours in these neonates. Testing glucose in each urine 
enables obtaining less blood tests in neonates with hy-
perglycemia (19).
1. Positive glucose in urine: When glucosuria is ≥1 (+) in 
urine, there is a risk for osmolarity change. If urine glu-
cose is ≥ 2 (+), the amount of glucose in the IV fluid is 
reduced by 1-2 mg / kg / min every 2-4 hours to reduce the 
amount of glucose to 4 mg / kg / min (3).
2. Negative glucose in urine: If glucose is required for 
calories, high glucose (200 mg / dl) levels are acceptable 
Şimşek et al. Neonatal Hyperglycemia, which threshold value, diagnostic 
approach and treatment?
S237
Turk Pediatri Ars 2018; 53(Suppl 1): S234-S238
as long as there is no glucose excretion or 1+ in urine. 
Blood glucose and urine glucose should be monitored ev-
ery 4 to 6 hours with dextrostix.
Currently, treatment of hyperglycemia that does not 
cause an increase in osmolarity and osmotic diuresis is 
not supported.
Sepsis should definitely be considered in all babies 
with hyperglycemia.
• The neonates should be fed immediately if they can 
be fed.
• Parenteral nutrition with high amino acid content 
should be initiated in the early period (4)
INSULIN is recommended if blood glucose levels> 250 mg 
/ dl and if glucosuria is present in 2 separate urine samples 
taken at 4 hours intervals and weight gain is not sufficient 
despite the reduction of glucose infusion (20, 21).
Bolus insulin therapy is not recommended consider-
ing the development of hypoglycemia. Insulin infusion 
treatment has been defined as appropriate for preterm 
newborns in Cochrane database and in a randomized, 
controlled study. Insulin treatment causes an increase in 
weight as well as controlling hyperglycemia.
Insulin treatment without bolus insulin:
• Insulin infusion at a rate of 0.01-0.05 U/kg/h is initi-
ated.
• Insulin is increased by 0.01 U/kg/h up to a maximum 
dose of 0.1 U/kg/h.
• The objective is to maintain the blood glucose level 
between 150 mg/dL and 200 mg/dL
• If the blood glucose level decreases to 180-200 mg/dL, 
insulin infusion is reduced by 50%.
• If the blood glucose level is <180 mg/dL, insulin infu-
sion is discontinued.
• If the blood glucose level is <150 mg/dL, insulin is dis-
continued and glucose infusion is increased by 2 mg/
kg/min.
The blood glucose level should be measured half an hour 
after each change in insulin infusion.
If hypoglycemia develops, insulin infusion is discontin-
ued and 2 ml / kg IV bolus is administered with 10% Dx. 
For rebound hyperglycemia the patient should be moni-
tored (20, 21).
Is insulin infusion necessary to prevent hyperglycemia 
in the early period?
In a study conducted with continuous glucose measure-
ment devices in VLBW babies, it was reported that sub-
jects who recieved standard hyperglycemia treatment 
and early insulin infusion in the early period experienced 
more hypoglycemia though they were hyperglycemic for 
a shorter period, NEC and ROP development and growth 
parameters were similar they developed sepsis at around 
28 days; however, mortality was higher and it was stated 
that there was no need for insulin infusion to prevent hy-
perglycemia in the early period (16).
Drugs causing hyperglycemia
1. The serum theophylline level should be measured in 
babies who receive theophylline in terms of toxicity 
resulting in potential hyperglycemia. If the level is 
high, theophylline should be discontinued or its dose 
should be adjusted. 
2. Maternal use of diazoxide: this drug may cause hy-
potension and tachycardia as well as hyperglycemia. 
Toxicity in babies is self-limiting and rare. 
3. Caffeine and phenytoin should be discontinued, if 
possible.
4. Steroid: their frequency and dose may be decreased.
5. Catecholamines
Hyperosmolarity: Rehydration is necessary. Formula is 
discontinued if hyperosmolarity is secondary to hyperos-
molar formula. Detailed formula use is explained.
In conclusion, in the neonatal period:
• The glucose value should be kept between 70 and 150 
mg/dL
• A blood glucose level of >150 mg/dL in term babies 
should be defined as hyperglycemia
• Early enteral nutrition should be initiated
• Parenteral amino acids should be initiated in the early 
period to prevent hyperglycemia
• Insulin should be used in persistent hyperglycemia 
despite decreased glucose infusion rate in newborns 
receiving parenteral nutrition treatment
• Insulin infusion is not needed in the early period to 
prevent hyperglycemia.
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Çıkar Çatısması: Yazarlar çıkar çatışması bildirmemişlerdir.
Mali Destek: Yazarlar bu çalışma için mali destek almadık-
larını beyan etmişlerdir.
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